8:06 AM ET
10-Q
Financial Results
Allarity Therapeutics Q3 2026 Results: Net Loss of $6.2M, Loss Widens
For the nine months ended September 30, 2026, Allarity Therapeutics reported a net loss of $12.4 million, an increase from the $7.9 million loss in the prior year period, primarily driven by higher research and development costs. The company's total stockholders' equity turned to a deficit of $2.3 million as of September 30, 2026, while cash and restricted cash increased to approximately $24.1 million.
- Key figure
- Net loss $6.2M